PE20190436A1 - Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1 - Google Patents

Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1

Info

Publication number
PE20190436A1
PE20190436A1 PE2018002326A PE2018002326A PE20190436A1 PE 20190436 A1 PE20190436 A1 PE 20190436A1 PE 2018002326 A PE2018002326 A PE 2018002326A PE 2018002326 A PE2018002326 A PE 2018002326A PE 20190436 A1 PE20190436 A1 PE 20190436A1
Authority
PE
Peru
Prior art keywords
binding
polypeptide
tnf family
antigen
molecule
Prior art date
Application number
PE2018002326A
Other languages
English (en)
Inventor
Stefan Seeber
Koller Claudia Ferrara
Christina Claus
Christian Klein
Maria Amann
Sandra Grau-Richards
Peter Bruenker
Pablo Umana
Viktor Levitski
Ekkehard Moessner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20190436A1 publication Critical patent/PE20190436A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se refiere a una molecula de union a antigeno que contiene trimero de ligando de la familia de TNF (Factor de Necrosis Tumoral) que comprende al menos un resto capaz de unirse especificamente a PD1 (proteina de muerte programada 1) y un primer y un segundo polipeptido unidos entre si por un enlace disulfuro (el primer polipeptido tiene 2 ectodominios de un miembro de la familia de ligandos de TNF o un fragmento del mismo, conectados entre si por un enlazador peptidico, mientras que el segundo polipeptido tiene un ectodominio de dicho miembro de la familia de ligandos de TNF o un fragmento del mismo), asi como a un polinucleotido aislado que codifica la molecula descrita lineas arriba (puede estar comprendido en un vector de expresion o en una celula hospedadora), y a composiciones farmaceuticas que contienen la molecula o un derivado (pueden ser 1 o mas y se puede anadir un agente terapeutico adicional) y al menos un excipiente farmaceuticamente aceptable (disolventes, tensioactivos, antioxidantes, entre otros). Tambien se refiere a ensayos para estudiar sus propiedades fisicas y quimicas y/o actividades biologicas, y metodos de produccion, recombinantes, terapeuticos y de tratamiento. La presente invencion es util para el tratamiento del cancer.
PE2018002326A 2016-05-13 2017-05-11 Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1 PE20190436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16169487.2A EP3243832A1 (en) 2016-05-13 2016-05-13 Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety

Publications (1)

Publication Number Publication Date
PE20190436A1 true PE20190436A1 (es) 2019-03-27

Family

ID=56014831

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018002326A PE20190436A1 (es) 2016-05-13 2017-05-11 Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1

Country Status (22)

Country Link
US (2) US20190185566A1 (es)
EP (2) EP3243832A1 (es)
JP (1) JP6801006B2 (es)
KR (1) KR20190004802A (es)
CN (1) CN109563146B (es)
AR (1) AR108453A1 (es)
AU (1) AU2017264548A1 (es)
BR (1) BR112018073289A2 (es)
CA (1) CA3023393A1 (es)
CL (1) CL2018003205A1 (es)
CO (1) CO2018012083A2 (es)
CR (1) CR20180538A (es)
IL (1) IL262843A (es)
MA (1) MA44973A (es)
MX (1) MX2018013675A (es)
PE (1) PE20190436A1 (es)
PH (1) PH12018502367A1 (es)
RU (1) RU2018143439A (es)
SG (1) SG11201810076WA (es)
TW (1) TW201805306A (es)
WO (1) WO2017194641A1 (es)
ZA (1) ZA201807581B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
MY192202A (en) 2015-10-02 2022-08-06 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
CA3131983C (en) 2015-11-18 2023-12-05 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
CA3039446A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
JP7122311B2 (ja) 2017-01-03 2022-08-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗４－１ｂｂクローン２０ｈ４．９を含む二重特異性抗原結合分子
CA3047708A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirpalpha-41bbl fusion protein and methods of use thereof
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
AU2018205888B2 (en) 2017-01-05 2021-09-02 Kahr Medical Ltd. A PD1-41BBL fusion protein and methods of use thereof
WO2018127918A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirp alpha-cd70 fusion protein and methods of use thereof
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018187215A1 (en) * 2017-04-03 2018-10-11 Merrimack Pharmaceuticals, Inc. Bispecific 4-1bb agonist molecules
MY201482A (en) 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
MY199406A (en) * 2017-04-05 2023-10-25 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
AR114284A1 (es) * 2018-04-13 2020-08-12 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
SG11202013167UA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
JP7221379B2 (ja) 2018-10-01 2023-02-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｆａｐクローン２１２を含む二重特異性抗原結合分子
AU2019410073B2 (en) 2018-12-21 2024-08-01 F. Hoffmann-La Roche Ag Tumor-targeted agonistic CD28 antigen binding molecules
CN110592140A (zh) * 2019-09-30 2019-12-20 王清路 Pd-1基因缺陷型pd-1-cart细胞制剂的制法
WO2021140130A1 (en) * 2020-01-09 2021-07-15 F. Hoffmann-La Roche Ag New 4-1bbl trimer-containing antigen binding molecules
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CN115836084A (zh) * 2020-05-15 2023-03-21 阿珀吉尼科斯股份公司 多特异性免疫调节剂
WO2023088876A1 (en) * 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
CN114984207B (zh) * 2022-05-09 2024-01-26 浙江特瑞思药业股份有限公司 一种抗pd-1纳米抗体制剂

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156905B (it) 1977-04-18 1987-02-04 Hitachi Metals Ltd Articolo di ornamento atto ad essere fissato mediante un magnete permanente
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2385347C (en) 1999-10-04 2009-12-15 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
JP2005524379A (ja) 2001-08-03 2005-08-18 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性の増強を伴う抗体グリコシル化改変体
CN100423777C (zh) 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
JP2007523602A (ja) * 2003-02-06 2007-08-23 マイクロメット アクツィエン ゲゼルシャフト 持続的なｔ細胞応答方法
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2003272065A1 (en) 2003-04-03 2004-10-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
DE602004018141D1 (de) 2003-07-04 2009-01-15 Affibody Ab Polypeptide mit bindungsaffinität für her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
PL2380911T3 (pl) 2003-11-05 2018-10-31 Roche Glycart Ag Cząsteczki wiążące antygen o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej
MXPA06006406A (es) 2003-12-05 2007-03-21 Adnexus Therapeutics Inc Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2.
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR101339628B1 (ko) * 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
EP2397155B1 (en) 2005-06-08 2017-12-13 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
NZ594510A (en) 2006-12-27 2012-06-29 Harvard College Compositions and methods for the treatment of infections and tumors
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
BRPI0812913B8 (pt) 2007-06-18 2021-05-25 Merck Sharp & Dohme anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2195347A1 (en) 2007-08-17 2010-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
KR101001360B1 (ko) 2008-06-16 2010-12-14 (주)기가레인 전자 기기의 접지에 전기적으로 연결되는 인쇄회로기판
PL2310509T3 (pl) 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
JP2012501670A (ja) 2008-09-12 2012-01-26 アイシス・イノベーション・リミテッド Ｐｄ−１特異抗体およびその使用
WO2010029434A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
HUE028582T2 (en) 2008-11-28 2016-12-28 Univ Emory Method for determining the efficacy of PD-1 antagonists
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN103154038B (zh) 2010-08-13 2016-05-11 罗切格利卡特公司 抗成纤维细胞激活蛋白抗体及使用方法
CA2828289C (en) 2011-03-29 2020-07-21 Roche Glycart Ag Antibody fc variants
US9822179B2 (en) * 2011-04-01 2017-11-21 Universitat Stuttgart Recombinant TNF ligand family member polypeptides with antibody binding domain and uses therefor
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
BR112013032552A2 (pt) 2011-07-24 2017-12-12 Curetech Ltd variantes de anticorpos monoclonais humanizados imunomoduladores
JP6357467B2 (ja) * 2012-04-30 2018-07-11 バイオコン・リミテッド 標的化された／免疫調節性融合タンパク質およびそれを作製するための方法
CA2910278C (en) 2013-05-02 2021-09-28 Anaptysbio, Inc. Antibodies directed against programmed death-1 (pd-1)
CA2934028A1 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3224275B1 (en) * 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
EP3150636A1 (en) * 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
MY192202A (en) * 2015-10-02 2022-08-06 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
CN109071652B (zh) * 2016-05-11 2022-09-23 豪夫迈·罗氏有限公司 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子

Also Published As

Publication number Publication date
CN109563146A (zh) 2019-04-02
RU2018143439A3 (es) 2020-08-03
MX2018013675A (es) 2019-04-01
SG11201810076WA (en) 2018-12-28
EP3243832A1 (en) 2017-11-15
JP2019524053A (ja) 2019-09-05
PH12018502367A1 (en) 2019-09-09
CL2018003205A1 (es) 2019-01-18
AU2017264548A1 (en) 2018-11-22
CN109563146B (zh) 2022-10-14
CA3023393A1 (en) 2017-11-16
BR112018073289A2 (pt) 2019-03-19
MA44973A (fr) 2021-04-07
EP3455248A1 (en) 2019-03-20
US20230123178A1 (en) 2023-04-20
IL262843A (en) 2018-12-31
CR20180538A (es) 2019-01-10
KR20190004802A (ko) 2019-01-14
RU2018143439A (ru) 2020-06-15
CO2018012083A2 (es) 2018-11-22
US20190185566A1 (en) 2019-06-20
ZA201807581B (en) 2021-05-26
AR108453A1 (es) 2018-08-22
WO2017194641A1 (en) 2017-11-16
TW201805306A (zh) 2018-02-16
EP3455248B1 (en) 2021-06-30
JP6801006B2 (ja) 2020-12-16

Similar Documents

Publication Publication Date Title
PE20190436A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1
CO2020000357A2 (es) Receptores de células t novedosos, e inmunoterapia usando los mismos
PE20170896A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
CL2021002997A1 (es) Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535)
CO2019011688A2 (es) Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra cánceres positivos para prame
CO2019003951A2 (es) Proteínas de unión a cd123 y composiciones y métodos relacionados
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
PE20210746A1 (es) Metodo para el cribado ultrarrapido de la afinidad de complejos mhc-peptido en busca de ligandos de tcr
CR20190276A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
AR115389A1 (es) Anticuerpo antagonista de cd73
MX2020004741A (es) Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos.
BR112018016281A2 (pt) molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo
CR20190095A (es) Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos
MX2017014083A (es) Polipeptido de fusion anti-cancer.
AR085198A1 (es) Composicion farmaceutica
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
CR20170138A (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer
EA201791853A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака
AR087615A1 (es) Moleculas biespecificas de union a antigeno
CL2021001565A1 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores (divisional de la solicitud no. 201702407)
PE20191662A1 (es) Anticuerpos anti-il-5
EA201991444A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
AR098953A1 (es) Anticuerpo anti-adam17 (proteína desintegrina y metaloproteinasa-17) y su uso para el tratamiento de cáncer
AR111000A1 (es) Moléculas de unión biespecíficas que son capaces de unirse a cd137 y a antígenos tumorales, y usos de las mismas
EA201992002A1 (ru) Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением